Thomas Powles (Peter Schmid)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 48

Top Topics

Renal Cell Carcinoma

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Nature communications

Nature medicine

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Powles, Yen-Hwa Chang, Yoshiaki Yamamoto, Jose Munoz, Felipe Reyes-Cosmelli, Avivit Peer, Graham Cohen, Evan Y Yu, Anja Lorch, Abhishek Bavle, Blanca Homet Moreno, Julia Markensohn, Mackenzie Edmondson, Cai Chen, Razvan Cristescu, Carol Peña, Jared Lunceford, Seyda Gunduz
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial. Nature medicine (2024)
Robert J Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Gruenwald, Thomas E Hutson, Boris Alekseev, Sun Young Rha, Jaime R Merchan, Jeffrey C Goh, Aly-Khan A Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung-Hoo Hong, Howard Gurney, Maria Jose Mendez, Evgeny Kopyltsov, Sergey A Tjulandin, Teresa Alonso Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph Burgents, Cixin He, Chinyere E Okpara, Jodi-Ann Mckenzie, Toni K Choueiri, null null
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (11) (2024)
Alison Jane Birtle, Robert J Jones, John Chester, Rebecca Lewis, Katie Biscombe, Mark Johnson, Anthony Blacker, Richard T Bryan, James W F Catto, Ananya Choudhury, Prantik Das, Satinder Jagdev, Thomas Powles, John Wagstaff, Ka Ching Cheung, Fay H Cafferty, Emma C Hall
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Robert J Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Gruenwald, Thomas E Hutson, Boris Alekseev, Sun Young Rha, Jaime R Merchan, Jeffrey C Goh, Aly-Khan A Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung-Hoo Hong, Howard Gurney, Maria Jose Mendez, Evgeny Kopyltsov, Sergey A Tjulandin, Teresa Alonso Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph Burgents, Cixin He, Chinyere E Okpara, Jodi-Ann Mckenzie, Toni K Choueiri, null null
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (11) (2024)
Alison Jane Birtle, Robert J Jones, John Chester, Rebecca Lewis, Katie Biscombe, Mark Johnson, Anthony Blacker, Richard T Bryan, James W F Catto, Ananya Choudhury, Prantik Das, Satinder Jagdev, Thomas Powles, John Wagstaff, Ka Ching Cheung, Fay H Cafferty, Emma C Hall
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (13) (2024)
Robert J Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Gruenwald, Thomas E Hutson, Boris Alekseev, Sun Young Rha, Jaime R Merchan, Jeffrey C Goh, Aly-Khan A Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung-Hoo Hong, Howard Gurney, Maria Jose Mendez, Evgeny Kopyltsov, Sergey A Tjulandin, Teresa Alonso Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph Burgents, Cixin He, Chinyere E Okpara, Jodi-Ann Mckenzie, Toni K Choueiri, null null
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Robert J Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Gruenwald, Thomas E Hutson, Boris Alekseev, Sun Young Rha, Jaime R Merchan, Jeffrey C Goh, Aly-Khan A Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung-Hoo Hong, Howard Gurney, Maria Jose Mendez, Evgeny Kopyltsov, Sergey A Tjulandin, Teresa Alonso Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph Burgents, Cixin He, Chinyere E Okpara, Jodi-Ann Mckenzie, Toni K Choueiri, null null
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (11) (2024)
Robert J Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Gruenwald, Thomas E Hutson, Boris Alekseev, Sun Young Rha, Jaime R Merchan, Jeffrey C Goh, Aly-Khan A Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung-Hoo Hong, Howard Gurney, Maria Jose Mendez, Evgeny Kopyltsov, Sergey A Tjulandin, Teresa Alonso Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph Burgents, Cixin He, Chinyere E Okpara, Jodi-Ann Mckenzie, Toni K Choueiri, null null
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (11) (2024)
Alison Jane Birtle, Robert J Jones, John Chester, Rebecca Lewis, Katie Biscombe, Mark Johnson, Anthony Blacker, Richard T Bryan, James W F Catto, Ananya Choudhury, Prantik Das, Satinder Jagdev, Thomas Powles, John Wagstaff, Ka Ching Cheung, Fay H Cafferty, Emma C Hall
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (13) (2024)
Toni K Choueiri, Amber C Donahue, David A Braun, Brian I Rini, Thomas Powles, John B A G Haanen, James M G Larkin, Xinmeng Jasmine Mu, Jie Pu, Rosemary E Teresi, Alessandra di Pietro, Paul B Robbins, Robert J Motzer
Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma. Cancer discovery (2024)
Alison Jane Birtle, Robert J Jones, John Chester, Rebecca Lewis, Katie Biscombe, Mark Johnson, Anthony Blacker, Richard T Bryan, James W F Catto, Ananya Choudhury, Prantik Das, Satinder Jagdev, Thomas Powles, John Wagstaff, Ka Ching Cheung, Fay H Cafferty, Emma C Hall
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Alison Jane Birtle, Robert J Jones, John Chester, Rebecca Lewis, Katie Biscombe, Mark Johnson, Anthony Blacker, Richard T Bryan, James W F Catto, Ananya Choudhury, Prantik Das, Satinder Jagdev, Thomas Powles, John Wagstaff, Ka Ching Cheung, Fay H Cafferty, Emma C Hall
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (13) (2024)
Toni K Choueiri, Amber C Donahue, David A Braun, Brian I Rini, Thomas Powles, John B A G Haanen, James M G Larkin, Xinmeng Jasmine Mu, Jie Pu, Rosemary E Teresi, Alessandra di Pietro, Paul B Robbins, Robert J Motzer
Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma. Cancer discovery 14 (3) (2024)
Christopher J Sweeney, Russell Petry, Chang Xu, Merrida Childress, Jie He, David Fabrizio, Ole V Gjoerup, Samantha Morley, Timothy Catlett, Zoe June Assaf, Kobe Yuen, Matthew J Wongchenko, Kalpit Shah, Pratyush Gupta, Priti S Hegde, Lincoln W Pasquina, Sanjeev Mariathasan, Ryon P Graf, Thomas Powles
Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Alison Jane Birtle, Robert J Jones, John Chester, Rebecca Lewis, Katie Biscombe, Mark Johnson, Anthony Blacker, Richard T Bryan, James W F Catto, Ananya Choudhury, Prantik Das, Satinder Jagdev, Thomas Powles, John Wagstaff, Ka Ching Cheung, Fay H Cafferty, Emma C Hall
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Robert J Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Gruenwald, Thomas E Hutson, Boris Alekseev, Sun Young Rha, Jaime R Merchan, Jeffrey C Goh, Aly-Khan A Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung-Hoo Hong, Howard Gurney, Maria Jose Mendez, Evgeny Kopyltsov, Sergey A Tjulandin, Teresa Alonso Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph Burgents, Cixin He, Chinyere E Okpara, Jodi-Ann Mckenzie, Toni K Choueiri, null null
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (11) (2024)
Cristina Suárez, James M G Larkin, Poulam Patel, Begoña P Valderrama, Alejo Rodriguez-Vida, Hilary Glen, Fiona Thistlethwaite, Christy Ralph, Gopalakrishnan Srinivasan, Maria Jose Mendez, Ryan Hartmaier, Aleksandra Markovets, Aaron Prendergast, Bernadett Szabados, Kelly Mousa, Thomas Powles
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, Ignacio Duran, Simon J Crabb, Michiel S Van Der Heijden, Bernadett Szabados, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz, Andrew S Protheroe, Alain Ravaud, Denis Maillet, Maria Jose Mendez, Cristina Suarez, Mark Linch, Aaron Prendergast, Pieter-Jan van Dam, Diana Stanoeva, Sofie Daelemans, Sanjeev Mariathasan, Joy S Tea, Kelly Mousa, Romain Banchereau, Daniel Castellano
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nature medicine (2023)
A Gordon Robertson, Khyati Meghani, Lauren Folgosa Cooley, Kimberly A McLaughlin, Leigh Ann Fall, Yanni Yu, Mauro Antonio Alves Castro, Clarice S Groeneveld, Aurélien de Reyniès, Vadim I Nazarov, Vasily O Tsvetkov, Bonnie Choy, Daniele Raggi, Laura Marandino, Francesco Montorsi, Thomas Powles, Andrea Necchi, Joshua J Meeks
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nature communications 14 (1) (2023)
Ashish M Kamat, Andrea B Apolo, Marek Babjuk, Trinity J Bivalacqua, Peter C Black, Roger Buckley, Matthew T Campbell, Eva Compérat, Jason Alexander Efstathiou, Petros D Grivas, Shilpa Gupta, Neil J Kurtz, Donald Lamm, Seth P Lerner, Roger Li, David J McConkey, Joan Palou Redorta, Thomas Powles, Sarah P Psutka, Neal D Shore, Gary D Steinberg, Richard Sylvester, J Alfred Witjes, Matthew D Galsky
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
A Gordon Robertson, Khyati Meghani, Lauren Folgosa Cooley, Kimberly A McLaughlin, Leigh Ann Fall, Yanni Yu, Mauro Antonio Alves Castro, Clarice S Groeneveld, Aurélien de Reyniès, Vadim I Nazarov, Vasily O Tsvetkov, Bonnie Choy, Daniele Raggi, Laura Marandino, Francesco Montorsi, Thomas Powles, Andrea Necchi, Joshua J Meeks
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nature communications 14 (1) (2023)
Thomas Powles, Se Hoon Park, Claudia Caserta, Begoña P Valderrama, Howard Gurney, Anders Ullén, Yohann Loriot, Srikala S Sridhar, Cora N Sternberg, Joaquim Bellmunt, Jeanny B Aragon-Ching, Jing Wang, Bo Huang, Robert J Laliberte, Alessandra di Pietro, Petros D Grivas
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
A Gordon Robertson, Khyati Meghani, Lauren Folgosa Cooley, Kimberly A McLaughlin, Leigh Ann Fall, Yanni Yu, Mauro Antonio Alves Castro, Clarice S Groeneveld, Aurélien de Reyniès, Vadim I Nazarov, Vasily O Tsvetkov, Bonnie Choy, Daniele Raggi, Laura Marandino, Francesco Montorsi, Thomas Powles, Andrea Necchi, Joshua J Meeks
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nature communications 14 (1) (2023)
Naveen S Vasudev, Gemma Ainsworth, Sarah R Brown, Lisa M Pickering, Tom Waddell, Kate Fife, Richard Griffiths, Anand Sharma, Eszter Katona, Helen Howard, Galina Velikova, Anthony Maraveyas, Janet Brown, Carmel Pezaro, Mark Tuthill, Ekaterini Boleti, Amit Bahl, Bernadett Szabados, Rosamonde E Banks, Joanne Brown, Balaji Venugopal, Poulam Manubhai Patel, Ankit Jain, Stefan N Symeonides, Paul D Nathan, Fiona J Collinson, Thomas Powles
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Sherene Loi, Roberto Salgado, Thomas Powles, Javier Cortes, David W Cescon, Eric P Winer, Deborah L Toppmeyer, Hope S Rugo, Michelino De Laurentiis, Rita Nanda, Hiroji Iwata, Ahmad Awada, Antoinette R Tan, Yuan Sun, Vassiliki Karantza, Anran Wang, Lingkang Huang, Assieh Saadatpour, Razvan Cristescu, Jennifer Yearley, Jared Lunceford, Petar Jelinic, Sylvia Adams
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. JCO precision oncology 7 (2023)
Sherene Loi, Roberto Salgado, Thomas Powles, Javier Cortes, David W Cescon, Eric P Winer, Deborah L Toppmeyer, Hope S Rugo, Michelino De Laurentiis, Rita Nanda, Hiroji Iwata, Ahmad Awada, Antoinette R Tan, Yuan Sun, Vassiliki Karantza, Anran Wang, Lingkang Huang, Assieh Saadatpour, Razvan Cristescu, Jennifer Yearley, Jared Lunceford, Petar Jelinic, Sylvia Adams
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. JCO precision oncology 7 (2023)
A Gordon Robertson, Khyati Meghani, Lauren Folgosa Cooley, Kimberly A McLaughlin, Leigh Ann Fall, Yanni Yu, Mauro Antonio Alves Castro, Clarice S Groeneveld, Aurélien de Reyniès, Vadim I Nazarov, Vasily O Tsvetkov, Bonnie Choy, Daniele Raggi, Laura Marandino, Francesco Montorsi, Thomas Powles, Andrea Necchi, Joshua J Meeks
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nature communications 14 (1) (2023)
Francesca Jackson-Spence, Charlotte Toms, Luke Furtado O'Mahony, Julia Choy, Lucy Flanders, Bernadett Szabados, Thomas Powles
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future oncology (London, England) (2023)
Francesca Jackson-Spence, Charlotte Toms, Luke Furtado O'Mahony, Julia Choy, Lucy Flanders, Bernadett Szabados, Thomas Powles
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future oncology (London, England) (2023)
Francesca Jackson-Spence, Charlotte Toms, Luke Furtado O'Mahony, Julia Choy, Lucy Flanders, Bernadett Szabados, Thomas Powles
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future oncology (London, England) 19 (7) (2023)
Francesca Jackson-Spence, Charlotte Toms, Luke Furtado O'Mahony, Julia Choy, Lucy Flanders, Bernadett Szabados, Thomas Powles
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future oncology (London, England) 19 (7) (2023)
A Gordon Robertson, Khyati Meghani, Lauren Folgosa Cooley, Kimberly A McLaughlin, Leigh Ann Fall, Yanni Yu, Mauro Antonio Alves Castro, Clarice S Groeneveld, Aurélien de Reyniès, Vadim I Nazarov, Vasily O Tsvetkov, Bonnie Choy, Daniele Raggi, Laura Marandino, Francesco Montorsi, Thomas Powles, Andrea Necchi, Joshua J Meeks
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nature communications 14 (1) (2023)
Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, Juan Martín-Liberal, Sang Joon Shin, Terence W Friedlander, Diego Tosi, Chandler Park, Carlos Alberto Gomez Roca, Florence Joly Lobbedez, Daniel Castellano, Rafael Morales-Barrera, Irene Moreno-Candilejo, Aude Flechon, Kobe Yuen, Deepali Rishipathak, Kelly DuPree, Fiona Young, Francesca Michielin, Colby S Shemesh, Elizabeth E Steinberg, Patrick Williams, Jae Lyun Lee
Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Randomized Umbrella Study. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Francesca Jackson-Spence, Charlotte Toms, Luke Furtado O'Mahony, Julia Choy, Lucy Flanders, Bernadett Szabados, Thomas Powles
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future oncology (London, England) 19 (7) (2023)
Francesca Jackson-Spence, Charlotte Toms, Luke Furtado O'Mahony, Julia Choy, Lucy Flanders, Bernadett Szabados, Thomas Powles
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future oncology (London, England) 19 (7) (2023)
Simon J Crabb, Syed Hussain, Eileen Soulis, Samantha Hinsley, Laura Dempsey, Avril Trevethan, YeePei Song, Jim Barber, John Frew, Joanna Gale, Guy Faust, Susannah Brock, Ursula McGovern, Omi Parikh, Deborah Enting, Santhanam Sundar, Gihan Ratnayake, Kathryn Lees, Alison Jane Birtle, Thomas Powles, Robert J Jones
A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Robert J Motzer, Toni K Choueiri, David F McDermott, Thomas Powles, Yann-Alexandre Vano, Saurabh Gupta, Jin Yao, Celine Han, Ron Ammar, Simon Papillon-Cavanagh, Shruti S Saggi, M Brent McHenry, Petra Ross-MacDonald, Megan Wind-Rotolo
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. Journal for immunotherapy of cancer 10 (3) (2022)
Michiel S Van Der Heijden, Thomas Powles, Daniel Petrylak, Ronald de Wit, Andrea Necchi, Cora N Sternberg, Nobuaki Matsubara, Hiroyuki Nishiyama, Daniel Castellano, Syed Anwer Hussain, Aristotelis Bamias, Georgios Gakis, Jae-Lyun Lee, Scott T Tagawa, Ulka Vaishampayan, Jeanny B Aragon-Ching, Bernhard J Eigl, Rebecca R Hozak, Erik R Rasmussen, Meng Summer Xia, Ryan Rhodes, Sameera Wijayawardana, Katherine M Bell-McGuinn, Amit Aggarwal, Alexandra Drakaki
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature communications 13 (1) (2022)
Bernadett Szabados, Mariano Ponz-Sarvisé, Robson Machado, Diego Saldana, Edward E Kadel, Romain Banchereau, Fanny Bouquet, Marius Garmhausen, Thomas Powles, Carsten Schröder, null null
Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI). Clinical cancer research : an official journal of the American Association for Cancer Research 28 (18) (2022)
Pashtoon Murtaza Kasi, Gordon Fehringer, Hiroya Taniguchi, Naureen Starling, Yoshiaki Nakamura, Daisuke Kotani, Thomas Powles, Bob T Li, Lajos Pusztai, Vasily N Aushev, Ekaterina Kalashnikova, Shruti Sharma, Meenakshi Malhotra, Zachary P Demko, Alexey Aleshin, Angel A Rodriguez, Paul R Billings, Axel Grothey, Gilles Manceau, David Cunningham, Takayuki Yoshino, Scott Kopetz
Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO precision oncology 6 (2022)
Thomas Powles, Kobe C Yuen, Silke Gillessen, Edward E Kadel, Dana Rathkopf, Nobuaki Matsubara, Charles G Drake, Karim Fizazi, Josep M Piulats, Piotr J Wysocki, Gary L Buchschacher, Boris Alekseev, Begoña Mellado, Bogusława Karaszewska, Jennifer F Doss, Grozdana Rasuo, Asim Datye, Sanjeev Mariathasan, Patrick Williams, Christopher J Sweeney
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nature medicine 28 (1) (2022)
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A Climent, Daniel P Petrylak, Jae Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N Sternberg, Peter H O'Donnell, Thomas Powles, Elizabeth R Plimack, Dean F Bajorin, Arjun V Balar, Daniel Castellano, Toni K Choueiri, Stephane Culine, Winald R Gerritsen, Howard Gurney, David I Quinn, Jacqueline Vuky, Nicholas J Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros D Grivas
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (10) (2022)
Thomas Powles, Danielle Carroll, Simon Chowdhury, Gwenaelle Gravis, Florence Joly, Joan Carles, Aude Fléchon, Pablo Maroto, Daniel Petrylak, Frédéric Rolland, Natalie Cook, Arjun V Balar, Srikala S Sridhar, Matthew D Galsky, Petros Grivas, Alain Ravaud, Robert J Jones, Jan Cosaert, Darren Hodgson, Iwanka Kozarewa, Richard Mather, Robert McEwen, Florence Mercier, Dónal Landers
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nature medicine 27 (5) (2021)
Thomas Powles, Daniel P Petrylak, Jonathan E Rosenberg
Beyond Chemotherapy and Checkpoint Inhibitors: Weighing the Risks and Benefits of the Novel Therapies for Metastatic Urothelial Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (30) (2021)
Romain Banchereau, Ning Leng, Oliver A Zill, Ethan Sokol, Gengbo Liu, Dean Pavlick, Sophia Maund, Li-Fen Liu, Edward E Kadel, Nicole E Baldwin, Suchit Jhunjhunwala, Dorothee Nickles, Zoe June Assaf, Daniel Bower, Namrata Patil, Mark McCleland, David Shames, Luciana Molinero, Mahrukh A Huseni, Shomyseh Sanjabi, Craig Cummings, Ira Mellman, Sanjeev Mariathasan, Priti Hegde, Thomas Powles
Molecular determinants of response to PD-L1 blockade across tumor types. Nature communications 12 (1) (2021)
Thomas Powles, Zoe June Assaf, Nicole Davarpanah, Romain Banchereau, Bernadett E Szabados, Kobe C Yuen, Petros Grivas, Maha Hussain, Stephane Oudard, Jürgen E Gschwend, Peter Albers, Daniel Castellano, Hiroyuki Nishiyama, Siamak Daneshmand, Shruti Sharma, Bernhard G Zimmermann, Himanshu Sethi, Alexey Aleshin, Maurizio Perdicchio, Jingbin Zhang, David S Shames, Viraj Degaonkar, Xiaodong Shen, Corey Carter, Carlos Bais, Joaquim Bellmunt, Sanjeev Mariathasan
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595 (7867) (2021)
Thomas Powles, Srikala S Sridhar, Yohann Loriot, Joaquim Bellmunt, Xinmeng Jasmine Mu, Keith A Ching, Jie Pu, Cora N Sternberg, Daniel P Petrylak, Rosa Tambaro, Louis M Dourthe, Carlos Alvarez-Fernandez, Maureen Aarts, Alessandra di Pietro, Petros D Grivas, Craig B Davis
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nature medicine (2021)
Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, Ignacio Duran, Simon J Crabb, Michiel S Van Der Heijden, Bernadett Szabados, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz, Andrew S Protheroe, Alain Ravaud, Denis Maillet, Maria Jose Mendez, Cristina Suarez, Mark Linch, Aaron Prendergast, Pieter-Jan van Dam, Diana Stanoeva, Sofie Daelemans, Sanjeev Mariathasan, Joy S Tea, Kelly Mousa, Romain Banchereau, Daniel Castellano
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nature medicine 25 (11) (2019)